MYC-Driven Pathways in Breast Cancer Subtypes
The transcription factor MYC (MYC proto-oncogene, bHLH transcription factor) is an essential signaling hub in multiple cellular processes that sustain growth of many types of cancers. MYC regulates expression of RNA, both protein and non-coding, that control central metabolic pathways, cell death, p...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2017-07-01
|
| Series: | Biomolecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-273X/7/3/53 |
| _version_ | 1819070263495491584 |
|---|---|
| author | Yassi Fallah Janetta Brundage Paul Allegakoen Ayesha N. Shajahan-Haq |
| author_facet | Yassi Fallah Janetta Brundage Paul Allegakoen Ayesha N. Shajahan-Haq |
| author_sort | Yassi Fallah |
| collection | DOAJ |
| description | The transcription factor MYC (MYC proto-oncogene, bHLH transcription factor) is an essential signaling hub in multiple cellular processes that sustain growth of many types of cancers. MYC regulates expression of RNA, both protein and non-coding, that control central metabolic pathways, cell death, proliferation, differentiation, stress pathways, and mechanisms of drug resistance. Activation of MYC has been widely reported in breast cancer progression. Breast cancer is a complex heterogeneous disease and treatment options are primarily guided by histological and biochemical evaluations of the tumors. Based on biochemical markers, three main breast cancer categories are ER+ (estrogen receptor alpha positive), HER2+ (human epidermal growth factor receptor 2 positive), and TNBC (triple-negative breast cancer; estrogen receptor negative, progesterone receptor negative, HER2 negative). MYC is elevated in TNBC compared with other cancer subtypes. Interestingly, MYC-driven pathways are further elevated in aggressive breast cancer cells and tumors that display drug resistant phenotype. Identification of MYC target genes is essential in isolating signaling pathways that drive tumor development. In this review, we address the role of MYC in the three major breast cancer subtypes and highlight the most promising leads to target MYC functions. |
| first_indexed | 2024-12-21T17:03:10Z |
| format | Article |
| id | doaj.art-900c530a15c94e6e8adedf7c89819cb0 |
| institution | Directory Open Access Journal |
| issn | 2218-273X |
| language | English |
| last_indexed | 2024-12-21T17:03:10Z |
| publishDate | 2017-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomolecules |
| spelling | doaj.art-900c530a15c94e6e8adedf7c89819cb02022-12-21T18:56:35ZengMDPI AGBiomolecules2218-273X2017-07-01735310.3390/biom7030053biom7030053MYC-Driven Pathways in Breast Cancer SubtypesYassi Fallah0Janetta Brundage1Paul Allegakoen2Ayesha N. Shajahan-Haq3Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USADepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USADepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USADepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USAThe transcription factor MYC (MYC proto-oncogene, bHLH transcription factor) is an essential signaling hub in multiple cellular processes that sustain growth of many types of cancers. MYC regulates expression of RNA, both protein and non-coding, that control central metabolic pathways, cell death, proliferation, differentiation, stress pathways, and mechanisms of drug resistance. Activation of MYC has been widely reported in breast cancer progression. Breast cancer is a complex heterogeneous disease and treatment options are primarily guided by histological and biochemical evaluations of the tumors. Based on biochemical markers, three main breast cancer categories are ER+ (estrogen receptor alpha positive), HER2+ (human epidermal growth factor receptor 2 positive), and TNBC (triple-negative breast cancer; estrogen receptor negative, progesterone receptor negative, HER2 negative). MYC is elevated in TNBC compared with other cancer subtypes. Interestingly, MYC-driven pathways are further elevated in aggressive breast cancer cells and tumors that display drug resistant phenotype. Identification of MYC target genes is essential in isolating signaling pathways that drive tumor development. In this review, we address the role of MYC in the three major breast cancer subtypes and highlight the most promising leads to target MYC functions.https://www.mdpi.com/2218-273X/7/3/53breast cancerERHER2TNBCdrug resistance |
| spellingShingle | Yassi Fallah Janetta Brundage Paul Allegakoen Ayesha N. Shajahan-Haq MYC-Driven Pathways in Breast Cancer Subtypes Biomolecules breast cancer ER HER2 TNBC drug resistance |
| title | MYC-Driven Pathways in Breast Cancer Subtypes |
| title_full | MYC-Driven Pathways in Breast Cancer Subtypes |
| title_fullStr | MYC-Driven Pathways in Breast Cancer Subtypes |
| title_full_unstemmed | MYC-Driven Pathways in Breast Cancer Subtypes |
| title_short | MYC-Driven Pathways in Breast Cancer Subtypes |
| title_sort | myc driven pathways in breast cancer subtypes |
| topic | breast cancer ER HER2 TNBC drug resistance |
| url | https://www.mdpi.com/2218-273X/7/3/53 |
| work_keys_str_mv | AT yassifallah mycdrivenpathwaysinbreastcancersubtypes AT janettabrundage mycdrivenpathwaysinbreastcancersubtypes AT paulallegakoen mycdrivenpathwaysinbreastcancersubtypes AT ayeshanshajahanhaq mycdrivenpathwaysinbreastcancersubtypes |